NEW YORK, March 05, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Vodafone Group Public Limited Company ("Vodafone") (NASDAQ:VOD) ADRs between February 11, 2015 and January 11, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-sbm/vodafone-group-public-limited-company?wire=2. There is no cost or obligation to you.
According to the complaint, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that Vodafone had contravened Australian law by permitting customers to purchase pre-paid mobile phones without first verifying their identities.
On January 10, 2018, the Australian Communications and Media Authority (“ACMA”) issued a press release disclosing that, following an investigation into Vodafone Australia, it determined that the Company had “failed to verify the identity of at least 1,028 customers before activating their prepaid mobile services.” Upon this news, Vodafone ADRs declined from a closing price of $32.60 on January 9, 2018, to a closing price of $31.44 on January 11, 2018.
If you suffered a loss in Vodafone you have until March 20, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/vodafone-group-public-limited-company?wire=2.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]


Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Anta Sports Expands Global Footprint With Strategic Puma Stake
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Samsung Electronics Shares Jump on HBM4 Mass Production Report
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



